https://www.selleckchem.com/pr....oducts/dorsomorphin-
Statistical analysis showed that most CTV and rectum parameters were significantly larger for SA plans than for DA plans (P less then 0.05). Furthermore, SA plans had fewer MUs and were less complex (P less then 0.05). The significant differences observed had no clinical significance, indicating that both plans are comparable in terms of target and OAR dosimetry when ID is considered. The use of SA plans is recommended for prostate cancer VMAT because they can be delivered in shorter treatment times than DA plans, and therefor